Kestra Medical Technologies, Ltd. (KMTS)
NasdaqGS
Price as at 1 Oct 2026, 22:03 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Kestra Medical Technologies, Ltd. trades at $27.12. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Kestra Medical Technologies, Ltd.
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at elevated risk of sudden cardiac arrest (SCA) during vulnerable periods of recovery. Its platform provides ASSURE Wearable Cardioverter Defibrillator (WCD), which continuously monitors patient heart rhythms and automatically delivers defibrillation therapy when life-threatening ventricular arrhythmias are detected; digital patient engagement and clinical workflow solutions designed to improve patient adherence, support care coordination, and provide actionable clinical insights throughout the recovery process; and integrated platform generates continuous cardiac rhythm data and clinically actionable insights. Kestra Medical Technologies, Ltd. was founded in 2014 and is based in Kirkland, Washington.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Common questions
Where does SteadyShares get its KMTS data?
Fundamentals for KMTS come from company filings and exchange data, as listed on NasdaqGS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 22:03 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for KMTS, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.